Search Results - william+dynan

14 Results Sort By:
High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin
Abstract: Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer. Researchers at the National Cancer Institute’s...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Ira Pastan, Jessica Hong, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, HO, MESOTHELIN, Mesothelioma, Recombinant Immunotoxins, RITs
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma
Abstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed....
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Carol Thiele Galetto, Nan Li, Rosa Nguyen, Rosandra Kaplan
Keywords(s): CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care  are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov
Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming
Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies
Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Dan Li
Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-1
Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
PMU-Embedded Analytics for Online Event Detection and Classification in Power Grids
The energy requirement of the world is increasing exponentially every year. With the power demand sites concentrated in the region with the highest population density, energy production sites must be located remotely. This isolation requires lengthy and complicated grids to be designed and manufactured to transmit power over long distances. Grid failures...
Published: 7/30/2024   |   Inventor(s): Payman Dehghanian, Shiyuan Wang, Li Li
Keywords(s):  
Category(s): Technology Classifications > Industrial or Consumer Tech > Energy Infrastructure and Environment
GA Tech has lead - Microirradiator for Treatment of Skin Tumors
Current State of the Art: The incidence of cancer is rising worldwide, with more than 11 million cases recorded annually. Incidence is expected to increase further, driven by rising life expectancy rates and aging global population. This is expected to increase the demand in the radiation therapy market which is currently experiencing technological...
Published: 4/28/2020   |   Inventor(s): Jiri Janata, Jennifer Steeb, Miraslawa Josowicz, William Dynan, Wendy Kuhne
Keywords(s): Radiation, Targeting
Category(s): Medical Devices
Sensitive Detection of Peptide Fragments Specific to Galectin-3 for the Detection and Monitoring of Well-differentiated Thyroid Cancer, Head and Neck Cancer, Lung Cancer, Colorectal Cancer and Other Cancers and Disease States
Current State of the Art:The detection of head and neck cancers, i.e. thyroid cancers, colorectal and other types of cancers are normally done via MRI or other non-specific tests. Problems with the Current Art:Such tests are not as accurate or time sensitive to identify the progression of the tumor in its early stage.Advantages of the Novel Invention:...
Published: 4/28/2020   |   Inventor(s): Paul Weinberger, John Koomen, William Dynan, David Terris, Sunny Khichi, Mark Merkley
Keywords(s): Cancer, Diagnostics, Peptides
Category(s): Diagnostics
1 2